https://www.selleckchem.com/products/sm-164.html
MET mutations in cfDNA may be a potential biomarker in patients with metastatic melanoma. Liquid biopsy using CAPP-Seq and ddPCR has the potential to detect tumor presence and mutations, especially when tissue biopsies are unavailable. MET mutations in cfDNA may be a potential biomarker in patients with metastatic melanoma. The main cause of mortality in locally advanced rectal cancer (LARC) is metastatic progression. The aim of the present study was to describe frequency, pattern and outcome of metastatic disease in a cohort of LARC pat
Like
Comment
Share
